Immunovant Retained Earnings Over Time
| IMVT Stock | USD 26.89 0.02 0.07% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Immunovant Performance and Immunovant Correlation. Immunovant |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunovant. If investors know Immunovant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunovant listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.21) | Return On Assets (0.55) | Return On Equity (0.92) |
The market value of Immunovant is measured differently than its book value, which is the value of Immunovant that is recorded on the company's balance sheet. Investors also form their own opinion of Immunovant's value that differs from its market value or its book value, called intrinsic value, which is Immunovant's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunovant's market value can be influenced by many factors that don't directly affect Immunovant's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunovant's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunovant is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunovant's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Retained Earnings Analysis
Compare Immunovant and related stocks such as Arbutus Biopharma Corp, Arcutis Biotherapeutics, and Legend Biotech Corp Retained Earnings Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABUS | (20.5 M) | (253.5 M) | (230.2 M) | (167 M) | (205.9 M) | (267 M) | (651.1 M) | (738.1 M) | (805.2 M) | (970.1 M) | (1 B) | (1.1 B) | (1.2 B) | (1.3 B) | (1.2 B) |
| ARQT | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (24.3 M) | (66.3 M) | (201.9 M) | (408.3 M) | (719.8 M) | (981.9 M) | (932.8 M) |
| LEGN | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 5.7 M | (127.3 M) | (430.8 M) | (817 M) | (966.5 M) | (1.5 B) | (1.4 B) |
| PTGX | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (27.4 M) | (64.6 M) | (101.5 M) | (140.5 M) | (217.7 M) | (283.8 M) | (409.4 M) | (536.8 M) | (615.7 M) | (584.9 M) |
| AKRO | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (86.6 M) | (130.3 M) | (209.5 M) | (310.3 M) | (422.3 M) | (574.1 M) | (545.4 M) |
| MDGL | (64.5 M) | (398.4 M) | (461.2 M) | (551.4 M) | (637.6 M) | (706.2 M) | (75.3 M) | (106.5 M) | (139.3 M) | (223.2 M) | (425.5 M) | (667.3 M) | (962.7 M) | (1.3 B) | (1.3 B) |
| APLS | (13.8 M) | (13.8 M) | (13.8 M) | (13.8 M) | (24.6 M) | (71.1 M) | (98.3 M) | (149.3 M) | (276.8 M) | (581.5 M) | (926.3 M) | (1.7 B) | (2.3 B) | (2.8 B) | (2.7 B) |
| ETNB | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (73.6 M) | (123.1 M) | (213.2 M) | (315.2 M) | (457.4 M) | (434.6 M) |
| PLRX | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (36.6 M) | (71.5 M) | (76.3 M) | (117.8 M) | (215.1 M) | (338.4 M) | (499.7 M) | (474.8 M) |
| ACLX | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (33 M) | (65.1 M) | (130.1 M) | (318.8 M) | (389.5 M) | (370 M) |
| STOK | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (25.7 M) | (58 M) | (110.3 M) | (196.1 M) | (297.1 M) | (401.8 M) | (381.8 M) |
| BPMC | (41.9 M) | (41.9 M) | (41.9 M) | (41.9 M) | (82.2 M) | (135 M) | (207.5 M) | (355.6 M) | (597.5 M) | (945.2 M) | (631.4 M) | (1.3 B) | (1.8 B) | (2.3 B) | (2.2 B) |
| DAWN | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (56.8 M) | (127.5 M) | (269.7 M) | (458.6 M) | (435.7 M) |
Immunovant and related stocks such as Arbutus Biopharma Corp, Arcutis Biotherapeutics, and Legend Biotech Corp Retained Earnings description
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.My Equities
My Current Equities and Potential Positions
| Immunovant | IMVT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 26.89
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.